Best Life Sciences Companies in Taiwan
The 245 best Life Sciences companies in Taiwan in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: TaiGen Biotechnology.
Taiwan's Life Sciences sector is moving fast, and this page ranks the best companies doing it, ordered by disclosed equity funding and recent momentum across 245 tracked firms. Total disclosed funding sits at $490M, with Aprinoia leading the pack at $51M, AP Biosciences close behind at $38M, and Brim Biotechnology rounding out the top tier at $20M. No unicorns yet, but the pipeline feels genuinely loaded. Backers like Taiwania Capital, CDIB Capital Group, and Diamond Biofund are writing the checks that matter. And if you want a read on where institutional appetite is pointing globally, Morgan Stanley's recent lift on life science tool stocks tracks a broader CAGR of roughly 10.2% on a market sized near $167.8B, which is the tide lifting Taiwan's biopharma ambitions right now.
So what's actually accelerating the sector? Partly demographics, partly capital formation, partly the kind of cross-border deal activity you see when a TPG-backed life sciences firm files for a major IPO and reminds every regional founder that public exits are real. I'd also flag the digital health signal here: median install growth across life sciences and healthcare apps is running at roughly 43% year-on-year, which tells you adoption isn't theoretical. Taiwan's aging population and sustained public funding are structural, not cyclical.
- What Drives San Diego's Life Sciences Industry
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Taiwan
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TaiGen Biotechnology Developer of therapeutics for infectious diseases and cancer | $99M | 208 mo ago | Public | 51 | Ming-Chu Hsu Chairman & Ceo | PleskPHPCodeIgniter+5 | 216 patents Antiviral therapeutics targeting cap-dependent endonuclease and HCV protease enzymes | — |
| 2 | TaiMed Biologics Developing antibodies and small molecule for the treatment and prevention of HIV infections | $52M | 192 mo ago | Series B | 78 | James Chang Chairman & CEO | BootstrapIoniconsFont Awesome+12 | 12 patents HIV antibody‑drug conjugates and long‑acting protease inhibitor drug delivery formulations | — |
| 3 | APRINOIA Developer of diagnostics and therapeutics for neurodegenerative disorders | $51M | 53 mo ago | Series C | 15 | — | — | — | — |
| 4 | AP Biosciences Recombinant antibody therapeutics discovery and development platform | $38M | 24 mo ago | Public | 31 | — | PHPFacebook LoginYouTube+14 | 84 patents Bispecific immune‑checkpoint and co‑stimulatory antibodies for T‑cell cancer therapy | — |
| 5 | Foresee Pharmaceuticals Developer of injectables and NCEs for cancer and chronic diseases | $32M | 72 mo ago | Public | 15 | — | PleskPHPCodeIgniter+11 | 143 patents Patents concentrated in health & consumer products | — |
| 6 | Taiwan Liposome Company Developer of nanomedicines for oncology, ophthalmology, osteoarthritis and pain management | $27M | 79 mo ago | Public | 112 | — | PHPYouTubeLaravel+8 | 297 patents Liposomal and sustained‑release drug delivery systems for intra‑articular and systemic therapies | — |
| 7 | Elixiron Developer of immunotherapy for cancer and immunological diseases | $27M | 47 mo ago | Series A | 23 | DawTsun Shih Co-Founder & CSO | PHPApache HTTP ServerAxios+7 | — | — |
| 8 | ACT Genomics Clinical and research services in genomics for cancer | $20M | 69 mo ago | Acquired | 300 | Shu Chen Co-Founder & CSO | Webflowcore-jsjQuery+11 | 10 patents Cancer molecular diagnostics: gene fusion/variant detection kits and sequencing analysis software | 1 launch |
| 9 | BRIM Biotechnology Developer of therapeutics for orthopedics and ophthalmology diseases | $20M | 42 mo ago | Series E | 27 | Haishan Jang CEO | — | 87 patents Patents concentrated in health & consumer products | — |
| 10 | Senhwa Biosciences Developer of small molecules for treating cancer | $17M | 150 mo ago | Public | 16 | — | RubyYouTubeRuby on Rails+19 | 133 patents Novel tetracyclic quinolone small‑molecule therapeutics for cancer and RNA‑virus treatment | — |
| 11 | SYNCELL Developer of a microscopic system for the identification of proteins and biomarkers | $15M | 18 mo ago | Series A | 11 | Jung Liao Founder & CEO | WordPressMySQLPHP+24 | — | — |
| 12 | Hualian Biotechnology Provider of genetic testing and analysis technologies | $14M | 139 mo ago | Series A | — | Andrew Wang CEO | BootstrapYouTubeGSAP+16 | — | — |
| 13 | Anbogen Therapeutics Developer of precision cancer therapeutics | $12M | 28 mo ago | Series A | — | Tsu-An Hsu Founder & CEO | PHPCodeIgniterBootstrap+12 | 16 patents Novel crystalline drug forms and formulation kits for colorectal cancer therapeutics | — |
| 14 | Swissray Group High-end medical imaging devices using Direct Digital Radiography | $12M | 264 mo ago | Public | 92 | — | NginxGoogle Analytics | — | — |
| 15 | AnHorn Medicines Developer of therapeutics for cancer, neurology, and age-related diseases | $10M | 37 mo ago | Series A | — | Chu-Chiang Lin Chief Executive Officer | WordPressMySQLPHP+23 | 13 patents Bifunctional small‑molecule androgen‑receptor modulators for treating prostate cancer | 1 expansion |
| 16 | Amwise Diagnostics Online platform for health information search | $10M | 75 mo ago | Series B | 25 | Sean Lin Huang Co-Founder & CEO | — | — | — |
| 17 | Bened Biomedical Developer of probiotics for research and development | $10M | — | Series A | — | Frankie Cheng Founder & CEO | WixSentryBootstrap+14 | 54 patents Probiotic lactobacilli therapeutics and diagnostics for metabolic, neurological, and allergic disorders | 1 job opening |
| 18 | Surglasses Developer of orthopedics tool and surgical products | $6M | 31 mo ago | Seed | — | Min Wang CEO | WordPress Site EditorElementorWordPress+18 | — | — |
| 19 | GeneTex GeneTex is a manufacturer and supplier of bioreagents for life science research. | $4M | 171 mo ago | Early Stage | 11 | Joel Baseman CEO | Amazon Web ServicesMicrosoft AdvertisingHtmx+12 | — | 1 launch |
| 20 | Heroic-Faith Provider of AI-based device for lung disease diagnosis | $4M | 34 mo ago | Series A | 20 | Frank Wu Co-Founder | Node.jsUbuntuNginx+4 | 19 patents Digital stethoscope hardware and AI-driven auscultation audio analytics for clinical diagnostics | — |
| 21 | Apollo Medical Optics Developer of OCT-based medical imaging devices | $3M | 126 mo ago | Series A | — | — | WordPressMySQLPHP+26 | 37 patents Advanced optical imaging and interferometric systems for medical diagnostic applications | — |
| 22 | HippoScreen Developer of an EEG-based brain health diagnostic device for mental health | $1M | 77 mo ago | Seed | — | Yi-Hung Liu Co-Founder | PythonGoogle MapsDjango+12 | — | 1 partnership |
| 23 | FlowVIEW Tek Liquid monitoring and analysis systems | $1M | 72 mo ago | Seed | — | Kevin Lee Co-Founder | RubyRuby on RailsAmazon Web Services+15 | 32 patents Optical flow‑cell microscopy and image analysis systems for impurity monitoring in production | — |
| 24 | Medigen Vaccinology Taiwanese biotech company that develops cell-based human vaccines for H5N1 and Enterovirus 71 | $428K | 129 mo ago | Public | 103 | Charles Chen CEO | PleskPHPBootstrap+9 | — | — |
| 25 | Cancer Free Biotech CRO focused on providing testing and clinical development services for oncology drugs | $105K | 36 mo ago | Seed | 11 | — | Cart FunctionalityShopifyVisa+13 | — | — |
Top 12 Life Sciences companies in Taiwan
#1
Series A · Taipei, Taipei · founded 2020 · 11 employees$15Mraised▾
Developer of a microscopic system for the identification of proteins and biomarkers. By using proprietary optoproteomics technology it has developed Microscoop that is capable of identifying proteins. It uses automated AI-based recognition algorithms and photochemical labeling reagents, to identify and quantify novel proteins for discovery research and disease mechanism studies.
- Dec 2024Series A$15M
#2
Public · Taipei, Taipei · founded 2013 · 31 employees$38Mraised▾
AP Biosciences is a biotech company that has a therapeutic antibody discovery platform which can be used to generate antibodies against a broad range of target proteins including proteins, peptides, whole cells and haptens. The company's discovery pipeline covers screening/discovery, functionalization, in vitro and in vivo characterization and expression cell line generation. Their platform's central asset is the OmniMab human antibody phage display library which is a broad range, stable, diverse and validated library for the screening of therapeutic antibodies. The company partners with biopharma companies (such as Allgenesis Biotherapeutics, GeneTex, Abnova and CellMax Life) for its discovery programs, and has one IND (bi-specific Ab) and several pre-clinical candidates in its product pipeline.
- Jun 2024Series D$38M
- 2016Grant (prize money)—
- 2015Grant (prize money)—
#3
Series A · Taipei, Taipei · founded 2019$12.5Mraised▾
Developer of precision cancer therapeutics. It offers drug candidates ABT-101 a tyrosine kinase inhibitor targeting HER2 Exon20 insertion from solid tumor cancer, ABT-201 a KRAS inhibitor targeting non-small cell lung cancer, and ABT-301 a small molecule histone deacetylase inhibitor (HDACi).
- Jan 2024Series A$12.5M
#4
Seed · Taichung, Taichung City · founded 2017$6.5Mraised▾
Surgical Glasses is developing orthopedics tools and surgical products. The company has developed surgical glasses, anatomical structured surgical tables, and surgical simulation tools for biomedical engineering applications.
- Nov 2023Seed$6.5M
#5
Series E · Neihu, Taipei City · founded 2013 · 27 employees$20Mraised▾
Developer of therapeutics for orthopedics and ophthalmology diseases. The drug candidate BRM421 is an eye drop for moderate to severe dry eye, BRM423 for corneal regeneration, and BRM521 for the treatment of osteoarthritis. These drugs are short-chain peptide molecules derived from pigment epithelial that stimulate stem cell growth and promote wound healing.
- Dec 2022Series E$20M
#6
Series C · Taipei, Taipei · founded 2015 · 15 employees$51.1Mraised▾
Developer of diagnostics and therapeutics for neurodegenerative disorders. The company focuses on the development of tau, alpha-synuclein, and other proteins that target neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. The company's lead candidate is APNmAb005 a humanized anti-tau antibody specifically targeting human tau aggregates found in tau-related diseases including Alzheimer's Disease.
- Dec 2021Series C$40M
- May 2019Grant (prize money)—
- Jan 2018Series B$11.1M
- Seed—
#7
Series A · Taipei, Taipei · founded 2018 · 20 employees$4Mraised▾
Heroic is a provider of AI-based devices for lung disease diagnosis. The solution offers by the company is used in remote lung sound monitor and in COPD (Chronic Obstructive Pulmonary Disease). The device is also used or the ICU patients as wells as for the COVID-19 patients. The AI-based technology is used to monitor the respiratory rate for the different pathological conditions as respiratory stenosis, obstruction, spasm, pulmonary edema, inflammation, fibrosis, secretion, and infiltration. It also offers an image-based analysis.
- Aug 2023Series A$15.1M
- Mar 2022Series A$500K
- Jul 2020Series A$4M
#8
Series A · Taipei, Taipei · founded 2020$10Mraised▾
Developer of therapeutics for cancer, neurology, and age-related diseases. It offers protein degradation drugs which include AH-001 for the treatment of androgenetic alopecia. It also provides drugs for prostate cancer, lymphoma, pancreatic, and colorectal cancer, neurodegenerative disease, and others.
- Apr 2023Series A$10M
#9
Series A · Taipei, Taipei · founded 2016 · 23 employees$27Mraised▾
Developer of immunotherapy for cancer and immunological diseases. The company's drug candidates include EI-1071 for Alzheimer's disease, tenosynovial giant cell tumors, EI-001 for vitiligo, and others for cancer. The platform has developed the proprietary human single B cell cloning technology and anti-cytokine monoclonal antibodies for targeting the immunosuppressive tumor for cancer treatment.
- Jul 2022Grant (prize money)—
- Aug 2021Series A$27M
- Aug 2020Grant (prize money)$1M
#10
Public · Taipei, Taipei · founded 2001 · 51 employees$99Mraised▾
Developer of therapeutics for infectious diseases and cancer. The company focuses on the discovery, development, and commercialization of therapeutics to treat cancers, infectious diseases and diabetic complications. It markets Nemonoxacin, a drug-resistant anti-infection drug for community-acquired pneumonia. It is developing Burixafor (TG-0054) which is a potent and selective CXCR4 chemokine receptor antagonist.
- Jan 2009Series C$37M
- Nov 2005Grant (prize money)$3.5M
- Mar 2004Series B$38M
- Oct 2003Grant (prize money)$890K
#11
Public · Taipei, Taipei · founded 2011 · 15 employees$32.5Mraised▾
Foresee Pharmaceuticals develops injectables and NCEs for cancer, endocrine disorders, and inflammatory diseases. Its stabilized injectable formulation platform is primarily a controlled release drug delivery platform for small molecules, peptides, and other bioactive. Its lead candidate is in phase III trials for prostate cancer, and another candidate in phase II trials for COPD and asthma. In addition, it has other candidates for acromegaly, opioid dependence, diabetic retinopathy and alport syndrome in preclinical studies. Its pipeline candidates are FP-001 (Leuprolide) for prostate cancer, FP-004 (Buprenorphine) for opioid dependence, and FP-011 (Goserelin) for the breast cancer among others.
- 2020Post IPO—
- Feb 2016Series D$14.5M
- Oct 2014Series C$18M
- 2014Series C—
#12
Acquired · Taipei, Taipei · founded 2014 · 300 employees$20.5Mraised▾
ACT Genomics offers clinical and research services in genomics for cancer. Its clinical offerings include NGS panels for auto-immune disease (ACTImmune), colon cancer (ACTColon), gastric cancer (ACTGastric) and breast cancer (ACTBreast). It also provides pharmacogenomic panels ACTDrug and ACTOnco that help physicians tailor therapies according to the patient's genotype. In addition, the company provides custom genomic services for biopharma companies and research institutions.
- Sep 2020Series B—
- Sep 2018Series B—
- May 2016Series B$12.5M
- Feb 2015Series A$8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Taiwan
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 361 Taiwan-affiliated papers.
- Ministry of Education70
- National Taiwan University47
- Soochow University41
- China Medical University34
- National Health Research Institutes25
- Gene1→11
- Mutant1→7
- Fluorescence1→4
- Antimicrobial1→5
- Antibiotic resistance6
- Human health5
- Transmission (telecommunications)3
- Sustainability3
- Resistance (ecology)2
Where biotechnology is researched across Taiwan
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.